The Globe and Mail reports in its Friday, Feb. 28, edition that Stifel analyst Justin Keywood continues to rate Andlauer Healthcare Group "buy." The Globe's David Leeder writes in the Eye On Equities column that Mr. Keywood bumped his share target ahead by a loonie to $53. Analysts on average target the shares at $49.08. Keywood says in a note: "Andlauer reported strong Q4 EBITDA margins, 26 per cent (vs. 25.5-per-cent estimate), despite U.S. headwinds, leading to flat overall growth (up 2 per cent year-over-year estimate). We are encouraged with the margin strength in the context of 4- to 7-per-cent organic growth to return in 2025, factoring in 'mid-to-high' single digits in Canada (85 per cent of sales) and U.S. headwinds (15 per cent). The high margins convert to plenty of FCF, $100-million in 2025, bolstering dry powder for M&A, NCIB or SIB ($400-million capacity) with current leverage, 0.87 times. Andlauer trades at 11 times NTM [next 12-month] EBITDA, vs. a three-year low, nine times, high 15 times and lower margin U.S. trucking comps at nine times. We believe Andlauer should be valued closer to cold-storage peer, Lineage (LINE), with similar margins at 16 times."